centerforbiosimilars11 小时
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...
centerforbiosimilars1 天
The Banking of Biosimilars: Insights From a Leading Health Economist
Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...
centerforbiosimilars2 天
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2 天
BioRationality: No More Biosimilars—Just Biogenerics
Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...
centerforbiosimilars3 天
Lisa Lasita, PharmD, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3 天
Derek Burns, PharmD, MBA, BCPS, BCSCP
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3 天
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3 天
Josh Canavan, PharmD
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4 天
Understanding Biosimilars Through Education and PBM Formulary Perspective
Josh Canavan, PharmD, head of pharmacy at RazorMetrics, recommends key educational resources for biosimilars, and emphasizes the extensive research conducted before pharmacy benefit managers (PBMs) ...
centerforbiosimilars4 天
Biosimilars Rheumatology Roundup: January 2025
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
centerforbiosimilars5 天
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...